{"id":"W4406160646","doi":"10.1016/s0140-6736(24)02575-3","title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Hepatocellular carcinoma; Placebo; Internal medicine; Oncology; Double blind; Carcinoma; Sorafenib; Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007391036,0.0004765439,0.001369803,0.0001785631,0.0003357262,0.0001177793,0.0002622816,0.0001015909,0.0001150184],"category_scores_gemma":[0.00007619645,0.0003145656,0.0002386392,0.0004819469,0.0001197492,0.0001333023,0.00003870199,0.000277539,0.00001820945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001768982,"about_ca_system_score_gemma":0.00044206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002712833,"about_ca_topic_score_gemma":0.0001221617,"domain_scores_codex":[0.9975253,0.0002254545,0.0005720162,0.0005563506,0.0004460049,0.00067486],"domain_scores_gemma":[0.9980085,0.0006330907,0.0001874981,0.0008071756,0.0002070847,0.0001566851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464474,0.00194094,0.04262963,0.0004564615,0.001508576,0.0001600568,0.003812042,0.00001988607,0.00102049,0.00008270764,0.001048465,0.0008733788],"study_design_scores_gemma":[0.931514,0.005643569,0.001389194,0.0001201835,0.003732095,0.0000157149,0.001765206,0.04438629,0.01047165,0.00001994672,0.0006153554,0.0003267453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800491,0.0002469009,0.001454416,0.001050027,0.0004092286,0.01546727,0.00009232004,0.0001164167,0.001114355],"genre_scores_gemma":[0.9945256,0.00001695521,0.0004650844,0.0001577078,0.0005662111,0.002976201,0.0005503222,0.00006159276,0.0006803242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0443664,"threshold_uncertainty_score":0.9999306,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1038831164175795,"score_gpt":0.3283258552258007,"score_spread":0.2244427388082212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}